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Poster Session I S217In cord blood bank practice, the 6 obstetric factors given above
and CBU weight are generally known before the decision on further
processing is made. In the respective regression model with TNC as
dependent variable, the highest absolute b values were reached for
CBU weight (b5 0.70) and vaginal delivery (b5 0.33) followed by
the number of preceding pregnancies (b5-0.13). These factors
were also significant at p5 0.05.
The presented data can be applied to optimize cord blood bank
operations. As one result one could, for example, establish different
CBUminimumweights for further processing subject to birth route:
since CBUs from vaginal deliveries have higherWBC counts, the re-
spective minimum weight could be lower than that of CBUs from
sectios.159
DOUBLE UMBILICAL CORD BLOOD TRANSPLANTATION ACHIEVES UNI-
VERSAL ENGRAFTMENT BUT IS ASSOCIATED WITH CONSIDERABLE
TRANSPLANT-RELATED MORTALITY
Baltadakis, I., Karakasis, D., Manaka, A., Panitsas, F., Poulopoulou, Z.,
Delistrati, V., Bika, E., Garofalaki, M., Papageorgiou, M.,
Vasileiou, S., Gigantes, S., Apostolidis, J., Harhalakis, N.,
Nikiforakis, E. Evangelismos Hospital, Athens, Greece
The applicability of umbilical cord blood transplantation (UCBT)
is limited by inadequate cell dose especially for adult patients. Infu-
sion of 2 partially HLA-matched units has been shown to facilitate
engraftment, and allows for transplantation of patients for whom
a single unit of sufficient cell dose is not available. However, double
UCBT is associated with an increased risk of acute graft-versus-host
disease (aGVHD), which may impair the outcomes. From 8/2006 to
7/2009, 21 patients (female:male5 10:11) with high-risk acute mye-
loid (AML, n5 16) or lymphoblastic (ALL, n5 5) leukemia received
double UCBT in our center. The patients had a median age of 36
years (range: 16-60), and a median weight of 75 kg (range: 53-105).
The median time from diagnosis to UCBT was 10 months (range:
3-91). The disease phase at transplant was 1st complete remission
(CR1) in 10 patients, CR2 in 5, and $CR3 or resistant relapse in
6. The conditioning regimen was myeloablative in 16 (TBI-based:
7, busulfan-based: 9), and reduced-intensity in 5 patients. ATG
was administered during conditioning only in 1 patient. Cyclospor-
ine plus mycophenolate mofetil was used for aGVHD prophylaxis.
The majority of UCB units (34/42) were 4/6 antigen matched to re-
cipient at HLA-A, -B, and -DRB1. The median total doses of nucle-
ated andCD34+ cells at infusionwere 4.3 10^7/kg (range: 2.65-5.4
 10^7/kg) and 1.33  10^5/kg (range: 0.6-3.1  10^5/kg), respec-
tively. Neutrophil recovery was achieved in all but 1 patient at a me-
dian of 19 days [cumulative incidence (CI) by day 52, 95%]. The CI
of platelet recovery (.50,000/uL) was 62% by day 270, and occurred
at a median of 83 days (range: 32-193). Eighteen patients (CI, 85%)
developed aGVHD (grade II-IV: 18, III-IV: 5). Three of 12 evalu-
able patients, who survived for more than 100 days, developed
chronic GVHD (CI, 14%). Treatment-related mortality (TRM)
was 38% at day 100 and 52% at 1 year. Causes of TRM were infec-
tion (n5 6), GVHD (n5 3), and transplant-associated microangi-
opathy (n5 2). Disease relapse occurred in 5 patients (CI, 28.5%
at 1 year). The 2-year disease-free and overall survival is 24% and
28%, respectively. Five patients are alive and in CR, 10-38 months
after UCBT. In conclusion, double UCBT results in an excellent
rate of engraftment in adult recipients. However, further improve-
ments should focus on the reduction of early TRM, which is signif-
icantly high and might be attributed to the increased incidence of
aGVHD.160
FLUDARABINE, CYCLOPHOSPHAMIDE AND ANTITHYMOCYTE GLOBULIN
(ATG) AS CONDITIONING REGIMEN IN MATCHED RELATED AND UNRE-
LATED ALLOGENEIC STEM CELL TRANSPLANTATION FOR SEVERE
APLASTIC ANEMIA (SAA): THE M.D. ANDERSON CANCER CENTER TEN-
YEAR EXPERIENCE
Anderlini, P., Acholonu, S., Okoroji, G., Popat, U., Giralt, S.A.,
Shpall, E.J., Qazilbash, M., de Lima, M., Worth, L., Champlin, R.E.
The University of Texas M.D. Anderson Cancer Center, Houston, TXBackground: Total body irradiation (TBI) is often employed in
matched unrelated donor (MUD) allogeneic stem cell transplanta-
tion (allo-SCT) in SAA. However, even at low doses, TBI can cause
serious short- and long-term toxicities. In matched related donors
(MRD), outcome in SAA patients$ 40 years with high-dose cyclo-
phosphamide (CY)6ATG is poor due to graft rejection, GVHD
and organ failure. Aim: To explore feasibility of a fludarabine
(FLU)–based, high-dose ATG, TBI-free regimen in MUD (all
ages) and MRD (recipient. 40 years) allo-SCT.
Methods:Over a 10-year period (1999-2009), twenty SAA patients
underwent allo-SCT with a FLU-CY-ATG regimen from a MRD
(n5 7, all age$ 40) or a MUD (n5 13, any age). Median age was
34 years (range 1-59). Seven pts (33%) were$ 50 years old. Bone
marrow was used as SC source in all but four patients. Once the
regimen was standardized, it included (n5 13) FLU (30 mg/m
sq  4 days) intravenously (IV), CY (300 mg/m sq IV  4 days),
and thymoglobulin (THY, 3.75 mg/kg IV  3-4 days). Before
that, in seven patients doses were FLU 20-50 mg/m sq IV  4
days; CY 40-60 mg/kg IV  2-4 days; ATG IV 20-30 mg/kg
(horse product) or 3 mg/kg (THY) x 2-4 days. Median time
from diagnosis to allo-SCT was 12 months (2-244). Eleven pa-
tients (55%) were transplanted off study (active infection, poor or-
gan function, etc).
Results: Seventeen out of 19 evaluable patients engrafted (90%).
There were two secondary graft failures (10%). Median time to neu-
trophil recovery (i.e. absolute neutrophil count$ 500/mL) was 15
days (range 8-30). Chimerism studies indicated $90% donor-de-
rived engraftment in 16/19 evaluable patients (75%) and thirteen pa-
tients were 100% donor. Four out of 20 evaluable patients (20%)
developed acute grade II-IV GVHD, and 6/16 evaluable patients
(37%) developed chronic GVHD. Thirteen patients (62%) are alive
(including eight out of the last nine treated) with a median follow-up
of 30 months (3-112). Seven patients expired (graft rejection n5 1,
infection n5 2, GVHDn5 1, organ failure n5 1, EBV lymphopro-
liferative disorder/LPD n5 2). There was one early death (death\
day +30) and no known late graft failures.
Conclusion: Fludarabine-based, TBI-free for MRD and MUD
allo-SCT is feasible in this high-risk group (older age, active infec-
tion, poor organ function, etc), with high engraftment rates and
low early mortality. Presumably due to high-dose ATG, GVHD-
related incidence and mortality were low, although EBV LPD
was a drawback.161
MULTIPLE UNIT UMBILICAL CORD BLOOD TRANSPLANTATION (MU
UCBT) WITH TOTAL BODY IRRADIATION, ETOPOSIDE AND ANTITHYMO-
CYTE GLOBULIN FOR ADULT HEMATOLOGIC MALIGNANCY PATIENTS
Sobecks, R., Copelan, E., Kalaycio,M., Askar,M., Rybicki, L., Serafino, S.,
Serafin,M., Macklis, R., Dean, R., Pohlman, B., Andresen, S., Bolwell, B.
Cleveland Clinic, OH
MU UCBT is an alternative donor transplant approach for adult
hematologic malignancy (HM) pts. TBI and VP16 is an effective
conditioning regimen, but its utility in MU UCBT is not well
known. From 10/03-2/09 we enrolled 16 adult HM pts on a trial
with this regimen prior to MU-UCBT. Eligibility included lack of
an HLAmatched related or unrelated donor. Pts had to have at least
a 4/6HLAmatchedUCB unit with at least 0.5 107 nucleated cells/
kg and a 2ndUCB unit with at least a 4/6HLAmatch to the 1st UCB
unit. The minimum required cryopreserved TNC dose for both
units was 1  107/kg or an infused CD34+ cell dose of 1.5  105/
kg. Pts received TBI 1,320 cGy (days -7 to -4), VP16 60 mg/kg
(day -3) and ATG 30 mg/kg (days -3 to +1). GVHD prophylaxis: ta-
crolimus and mycophenolate. Median age was 47 yrs (range, 18-60)
and diagnoses were 8 AML, 3 CML, 2MDS, 1 ALL, 1 CLL 1NHL.
Median time from diagnosis to UCBT was 8 mos. The 1st UCB unit
infused (UCB1) included five 4/6, ten 5/6 and one 6/6 HLAmatches
with the recipient, and for the 2nd UCB unit (UCB2) with recipient
there were one 3/6, five 4/6, and ten 5/6 matches. Median thawed
TNC doses infused for UCB1 and UCB2 were 1.6  107/kg and
1.2  107/kg, respectively; thawed CD34+ cell doses were 0.6 
105/kg for both units.12 were evaluable for engraftment; 3 others
S218 Poster Session Ihad early deaths and 1 had graft failure. Sustained engraftment in the
12 was observed from 1 UCB unit in all cases. The winning unit was
UCB1 in 5 (42%) and it had larger median CD8 (p5 0.009) and
thawed CD34+ cell (p5 0.006) doses infused. Median time to
achieve T cell complete donor chimerism was 30 days. Median times
to neutrophil and platelet engraftment were 20 and 46 days, respec-
tively. Median time hospitalized was 39 days. Incidence of grade 2-4
and 3-4 acute GVHD was 19% and 6%, respectively; while for
chronic GVHD it was 31% and 25% for extensive stage. 6 developed
CMV infection and 15 had other infections. There have been 2
(13%) relapses (1MDS, 1AML). 8 pts (50%) remain alive at amedian
follow-up of 15 mos (range, 5-35). Deaths included 4 infections, 1
graft failure, 1 pulmonary toxicity, 1 CNS bleed, 1 relapse (AML).
Incidence of death at 1 and 2 yrs are 45% (6% relapse, 39% non-re-
lapse) and 59% (6% relapse, 53% non-relapse), respectively. We
conclude that TBI, VP16 and ATG conditioning for MU UCBT
is effective in adult HM pts. Further strategies to enhance immune
reconstitution and prevent infection post-transplant are warranted.162
LONG-TERM MIXED DONOR-DONOR CHIMERISM AFTER DOUBLE CORD
BLOOD TRANSPLANTATION: ADVANTAGEOUS?
Gertow, J.1, Berglund, S.1, Okas, M.1, Uzunel, M.1, Ka¨rre, K.2,
Mattsson, J.1, Uhlin, M.1,2 1Karolinska University Hospital Huddinge,
Stockholm, Sweden; 2Karolinska Institutet, Stockholm, Sweden
Double cord blood transplantation (DCBT) with two partially
matched cord blood units has successfully been implemented to cir-
cumvent limitations of graft cell dose. After DCBT sustained hema-
topoiesis is derived almost exclusively from only one of the donated
units. Nonetheless, we previously observed two of six evaluable
DCBT patients having mixed donor-donor chimerism still at 28
and 45 months post-transplantation, respectively. In the present
studyweutilize flowcytometry techniques for thefirst ever deep anal-
ysis of phenotype and functionality ofCB units in patients withmixed
donor-donor chimerism. Our results suggest that the two stable CB
units are phenotypically and functionally different: One unit with
more naı¨veT cells, lower cytokine production andhigher frequencies
of NK cells, and one with higher frequencies of well differentiated
and functional lymphocytes. Additionally, in comparison to control
patients with a single prevailingCB unit, the patients with donor-do-
nor chimerism exhibit less overall cytokine production and a smaller
fraction of memory T cells. Furthermore, our results indicate that
HLA C match of donor units may partly explain the development
of a donor-donor mixed chimerism.163
SAFETY OF T-CELL REPLETE HAPLOIDENTICAL STEM CELL TRANSPLAN-
TATION USING FLUDARABINE, MELPAHALAN AND THIOTEPA CONDI-
TIONING AND HIGH-DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE
Ciurea, S.O., de Lima, M., Kebriaei, P., Rondon, G., Saliba, R.,
McMannis, J., Andersson, B.S., Khouri, I.F., Giralt, S.,
Champlin, R.E. University of Texas M.D. Anderson Cancer Center,
Houston, TX
Haploidentical stem-cell transplantation (HaploSCT) has been
performed using a T-cell depleted (TCD) graft; however, a high
NRM, primarily related to infectious complications, has been the
main limitation of this approach.Wehypothesized thatT-cell replete
(TCR) haploidentical transplantation using high-dose post-trans-
plant cyclophosphamide (HDPTCy) is associated with improved
early outcomes in patients (pts) with advanced hematologic malig-
nancies treated with fludarabine, melphalan and thiotepa condition-
ing (FMT), regimen previously reported by us for TCDHaploSCT.
Methods: Eight consecutive pts with relapsed/refractory hemato-
logic malignancies (5 with AMLwith16-84%marrow blasts at trans-
plant, 2 with blast-phase and 1 chronic-phase CML) received
melphalan 140 mg/m2 I.V. on day -8, thiotepa 10 mg/m2 I.V. on
day -7, fludarabine 40 mg/m2 on days -6, -5, -4 and -3, and
HDPTCy 50 mg/kg/day on days +3 and +4 plus tacrolimus andmye-
cophenolate. Median age was 45 years (range 30-63). Three pts were
Caucasian and 5 of non-Caucasian origin (2 Asian, 2 Hispanic and 1
African-American). Donors were siblings for 3, children for 4, andparent for 1 pt, with a median of 6.5/10 allele matches (range 5-8).
All pts except one received a bone marrow graft.
Results: All 8 pts engrafted with 100% donor-derived hematopoi-
esis by PCR, and achieved remission after transplant. Median time
to neutrophil engraftment was 18 days (range 16-40) and platelet
engraftment 29 days (range 15-35, N5 6). Two patients with
anti-HLA-antibodies engrafted after 29 and 40 days, significantly
longer than the rest, 16-19 days, p\0.001). Two pts experienced
grade II aGVHD resolved with steroids, none cGVHD, and 2 pro-
gressed. After a median follow-up of 6 months, all pts are alive and
6 in remission. Infections were notably lower than previously re-
ported by us with TCD HaploSCT. Day-100 TRM and NRM at
6 months were both 0%, remarkable as compared with our previ-
ous experience with TCD HaploSCT which showed that approxi-
mately 50% the pts would have expired by 6 months post-
transplant. Overall survival at 8 months was 39% in the TCD
group (N5 28) as compared with 100% in the TCR group
(N5 8) (p5 0.03).
Conclusion: Although limited by the small number of patients,
TCR HaploSCT using FMT and HDPTCy appears a safer
approach to HaploSCT and yielded remarkable early results with
successful engraftment and zero TRM and NRM in all treated pts.
A protocol has been open for patient accrual at our institution.164
PRE-FORMED ANTI-HLA ANTIBODIES IN HEMATOPOIETIC STEM CELL
TRANSPLANT RECIPIENTS: DO THEY MATTER?
Gandhi, D.G.1, Longobardi, S.2, Stone, C.2, Epstein, R.B1, Holter, J.1
1University of Oklahoma Health Sciences Center, Oklahoma City, OK;
2OU Medical Center, Oklahoma City, OK
Sensitization to HLA antigens is an important consideration in
solid organ transplantation. Most data regarding the importance
of donor-specific antibodies (DSA) is derived from renal trans-
plants, where sensitization is clearly associated with an increased
risk of early graft loss. Therapy is directed at removal or reduction
of these antibodies and improved survival. The role of antibodies
in hematopoietic stem cell transplantation is less clear. Some stud-
ies suggest that anti-HLA antibodies are not significant unless
they are donor-specific. We describe the clinical outcome of
two patients, one with high titers of non-DSA and the other pos-
itive for DSA. Antibodies were determined using single HLA an-
tigens by solid-phase Luminex method. Mean fluorescence
intensity (MFI)$ 1500 was defined as positive. High resolution
HLA typing was performed. Patient one is a 44 y/o Native Amer-
ican woman with AML-M6 who underwent a reduced intensity
unrelated donor transplant. She had a broad range of activity
against several HLA antigens but did not have DSA. She initially
received IVIG followed by rituximab and cyclophosphamide with
no response. She successfully engrafted and subsequently has de-
veloped grade 2 GVHD. Day 100 PRA (percent panel reactive an-
tibody) continued to be positive. Patient two was a 52 y/o white
woman with MDS who underwent a total of 3 successive umbilical
cord blood transplants (CBT). She had high titers of Class I and
II antibodies which reacted with all donors tested. Non-reactive
donors could not be found. Attempted immunosuppression was
carried out with several doses of IVIG without response. She
failed to engraft following each CBT attempt and died with mar-
row failure. Preliminary data (in press) suggested a 44% incidence
of pre-formed Class I antibodies in marrow graft recipients. The
importance of non-DSA and/or minor histocompatibility sensiti-
zation in marrow graft rejection and GVHD remain to be clari-
fied. As described above, high titers of anti-HLA antibodies do
not preclude engraftment (patient 1) unless they are donor specific
(patient 2). The significance of DSA has been previously reported
by Takanashi et al. and is illustrated by the above cases. Treat-
ment of sensitization to donor specific antigens seems at present
to be unsatisfactory. Further studies will require an extensive
prospective data base to define relationships between clinical out-
come and approaches to therapy in sensitized marrow transplant
patients.
